SCHEMBL7250388

SCHEMBL7250388

O=C1CCc2c1n([N+](=O)[O-])c1ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.50
CREBBP Q92793 1/20 0.50
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39
MAOA P21397 4/20 0.38
MAPT P10636 2/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
MAOB P27338 1/20 0.35
KDM4E B2RXH2 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
XBP1 P17861 1/20 0.33
RAB9A P51151 1/20 0.33
PAX8 Q06710 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14701011 0.73 TP53 (0.51) TP53CREBBPALDH1A1TSHRMAOA
SCHEMBL8792194 0.73 ALDH1A1 (0.62) TP53CREBBPALDH1A1TSHRMAOA
SCHEMBL3557147 0.73 MAPT (0.46) ALDH1A1TSHRMAPTKDM4ENPSR1
SCHEMBL16201673 0.70 TP53 (0.51) TP53CREBBPALDH1A1TSHRMAOA
SCHEMBL17895740 0.68 KDM4E (0.61) TP53CREBBPALDH1A1TSHRMAOA
SCHEMBL30223561 0.68 KDM4E (0.66) TP53CREBBPALDH1A1TSHRMAOA
SCHEMBL22118133 0.68 KDM4E (0.66) TP53CREBBPALDH1A1TSHRMAOA
SCHEMBL5322539 0.67 TP53 (1.00) TP53CREBBPALDH1A1TSHRMAPT
SCHEMBL30395130 0.67 TP53 (1.00) TP53CREBBPALDH1A1TSHRMAPT
SCHEMBL11876810 0.66 HSD17B10 (0.38) TP53ALDH1A1MAPTALOX15NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030139609-A1 Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139609-A1 Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles DUT, CYC1, DHRS9 TP53 823/4885CREBBP 3904/4885ALDH1A1 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.